RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)

RBC Capital analyst Leonid Timashev maintained a Hold rating on Design Therapeutics (DSGN – Research Report) yesterday and set a price target of $4.00. The company’s shares closed yesterday at $4.69.

According to TipRanks, Timashev is a 4-star analyst with an average return of 19.0% and a 38.78% success rate. Timashev covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Biohaven Ltd., and Edgewise Therapeutics.

Design Therapeutics has an analyst consensus of Hold, with a price target consensus of $6.25.

DSGN market cap is currently $265M and has a P/E ratio of -3.93.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Design Therapeutics (DSGN) Company Description:

Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.